1. Home
  2. Labeler Index
  3. Major Pharmaceuticals
  4. 0904-7125
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Levetiracetam NDC 0904-7125 by Major Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

carton label - C4B27429 50A3 467C A5FF 7E49A01A1088 00

carton label - C4B27429 50A3 467C A5FF 7E49A01A1088 00

This is a prescription drug with the brand name Levitiracetam. It comes in a package of 100 tablets identified by the NDC codes 0904-7125-61 and 0804-7125. The tablets are unit-dosed at 750 mg strength. It may only be dispensed by a licensed pharmacist with a medication guide. The product insert contains complete dosage recommendations, prescribing information, cautions, and warnings. This drug needs to be stored at 20-25°C (68-77°F), and the package is not designed to be child-resistant.*

carton label - C4B27429 50A3 467C A5FF 7E49A01A1088 01

carton label - C4B27429 50A3 467C A5FF 7E49A01A1088 01

This is a description of a medication named Levetiracetam provided by the Major pharmaceutical company. The medication is available in tablet form and comes in a unit dose package. The package contains 100 tablets, each containing 500 mg of Levetiracetam USP. The recommended dosage is not indicated but can be found in the product insert or complete precautions and warnings. The package is not child-resistant and should be stored at temperatures between 20-25°C (68-77°F) with excursions permitted up to 15-30°C (55-86°F) as per USP standards. No other information is available from the text provided.*

carton label - C4B27429 50A3 467C A5FF 7E49A01A1088 02

carton label - C4B27429 50A3 467C A5FF 7E49A01A1088 02

This is a description of a medication called Levetiracetam Tablets USP made by Major with NDC number 0904-7123-61 and dispensed in a unit dose. The medication comes in a package with 100 tablets that should be stored at a temperature between 20 and 25°C. The pharmacist is instructed to dispense the medication with a medication guide. The insert/med guide can be found on Variaorpharaceuticals.com. The text also includes a warning to keep the medication and all drugs out of reach of children as the unit dose package is not child-resistant.*

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

This is a figure (Figure 2) showing the responder rate (250% reduction from baseline) in Study 2 for a certain drug. The figure depicts the percentage of patients who responded to the drug at different dosages (levetiracetam 1000mg/day and 2000mg/day) compared to placebo. There is a statistically significant difference noted between the patients taking the drug at 2000mg/day and the placebo group.*

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

The figure shows the responder rate in Study 3, with a greater than 50% reduction from baseline. The percentage for placebo was 14.4%, while the percentage for Levetiracetam 3000 mg/day was 45%. The difference was statistically significant.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

The figure shows the responder rate in Study 4, with a 50% reduction from baseline. The percentage for the placebo group is 44.6% and for the Levetiracetam group is 45%. The graph indicates a statistically significant difference between the two groups.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

The figure shows the Responder Rate for patients aged 1 month to less than 4 years in Study 5, with a reduction of more than 50% from baseline. Lovetracatam (4-58) had a statistically significant result compared to the placebo.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

The figure shows the responder rate in PGTC seizure frequency per week in Study 7. The percentage reductions from the baseline are plotted on the y-axis, with 100% at the top and 0% at the bottom. The x-axis shows the treatment groups, with placebo and Levetiracetam. The responder rates were 72.2% for Levetiracetam and 45.2% for placebo. The difference between the two groups was statistically significant. Nine percent of patients in the study exhibited no response.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.